motherlodetv.net
Goldplay Exploration Ltd. (TSXV: GPLY, OTCQB: GLYXF) (“Goldplay” or the “Company”), is pleased to announce that the Company has closed the final tranche of its non-brokered private placement (the “Offering“) previously announced on November 19, 2018 and has issued 1,244,166 units for gross proceeds of $273,716.52. Total gross proceeds raised under all tranches of this offering was $1,499,960.
FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced that it is the featured company in the CannaInvestor Magazine December 2018 Issue. CannaInvestor Magazine is the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and the financial media. The digital version of the magazine is accessible and free to all subscribers who enter their email address. FSD Pharma’s cover feature can be found by clicking on this link https://joom.ag/0j5a or visiting CannaInvestor Magazine’s website www.cannainvestormag.ca.
Canadian Orebodies Inc. (the “Company”) (TSXV:CORE) is pleased to announce that the first phase of drilling has been completed on the Company’s Wire Lake project, consisting of the Black Raven, Goodchild, Sprucejack, and Wire Lake properties.
Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) announces that it’s option partner, Azincourt Energy Corp. (“Azincourt”) has provided an update regarding its winter work program at the East Preston uranium project located in the southwestern Athabasca Basin, Saskatchewan, Canada.
White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the “Company) is pleased to announce the discovery of additional high-grade gold mineralization outside of the previously drilled area on the Vertigo target at its JP Ross property, Yukon, Canada, stepping out as much as 300m in multiple directions. Additional surface samples have also identified new zones of high-grade gold mineralization in the areas surrounding the Vertigo target, further expanding the footprint of the high-grade mineralized system to 2,200m x 650m, as well as on other targets along the structural trend which has now been identified to extend 18km on the JP Ross Property. These results significantly increase the size and scale of the Company’s recent discovery on its JP Ross property, discovered through its systematic and data driven regional exploration program backed by partners Agnico Eagle Mines Limited (TSX: AEM, NYSE: AEM) and Kinross Gold Corp (TSX: K, NYSE: KGC).
MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) is pleased to announce receipt of the independent, 3rd party scale up and technology engineering review of the Company’s rapid lithium extraction technology for geothermal implementation in the Western United States. The report provides recommendations to implement large-scale application of the technology, including:
White Gold Corp. (TSX.V: WGO, OTC – Nasdaq Intl: WHGOF, FRA: 29W) (the “Company) is pleased to announce additional Reverse Circulation (“RC”) drill results and trenching results from the Vertigo target on the JP Ross property, Yukon, Canada. These results included a significant extension of the discovery Reverse-Air-Blast (“RAB”) drill hole which extended the mineralization at depth and encountered a deeper zone of high-grade gold. The trenching performed further defined the mineralization at Vertigo and will allow the previously identified gold zones to be extrapolated to additional drill targets.
FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9), which, through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the “Agreement”) with World Class Extractions Inc. (“World Class”), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World Class is also in the process of completing its own previously announced reverse takeover of CBD Med Research Corp. (the “RTO”), and submitted its initial listing application to the Canadian Securities Exchange (the “CSE”) late last week.
FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018.
